Skip to main content
Top
Published in: Cancer Cell International 1/2020

Open Access 01-12-2020 | Research

Identification of a competing endogenous RNA network associated with prognosis of pancreatic adenocarcinoma

Authors: Wanqing Weng, Zhongjing Zhang, Weiguo Huang, Xiangxiang Xu, Boda Wu, Tingbo Ye, Yunfeng Shan, Keqing Shi, Zhuo Lin

Published in: Cancer Cell International | Issue 1/2020

Login to get access

Abstract

Background

Emerging evidence suggests that competing endogenous RNAs plays a crucial role in the development and progress of pancreatic adenocarcinoma (PAAD). The objective was to identify a new lncRNA-miRNA-mRNA network as prognostic markers, and develop and validate a multi-mRNAs-based classifier for predicting overall survival (OS) in PAAD.

Methods

Data on pancreatic RNA expression and clinical information of 445 PAAD patients and 328 normal subjects were downloaded from The Cancer Genome Atlas (TCGA), International Cancer Genome Consortium (ICGC) and Genotype-Tissue Expression (GTEx). The weighted correlation network analysis (WGCNA) was used to analyze long non-coding RNA (lncRNA) and mRNA, clustering genes with similar expression patterns. MiRcode was used to predict the sponge microRNAs (miRNAs) corresponding to lncRNAs. The downstream targeted mRNAs of miRNAs were identified by starBase, miRDB, miRTarBase and Targetscan. A multi-mRNAs-based classifier was develop using least absolute shrinkage and selection operator method (LASSO) COX regression model, which was tested in an independent validation cohort.

Results

A lncRNA-miRNA-mRNA co-expression network which consisted of 60 lncRNAs, 3 miRNAs and 3 mRNAs associated with the prognosis of patients with PAAD was established. In addition, we constructed a 14-mRNAs-based classifier based on a training cohort composed of 178 PAAD patients, of which the area under receiver operating characteristic (AUC) in predicting 1-year, 3-year, and 5-year OS was 0.719, 0.806 and 0.794, respectively. The classifier also shown good prediction function in independent verification cohorts, with the AUC of 0.604, 0.639 and 0.607, respectively.

Conclusions

A novel competitive endogenous RNA (ceRNA) network associated with progression of PAAD could be used as a reference for future molecular biology research.
Appendix
Available only for authorised users
Literature
1.
3.
go back to reference Spanier BW, Dijkgraaf MG, Bruno MJ. Epidemiology, aetiology and outcome of acute and chronic pancreatitis: an update. Best Pract Res Clin Gastroenterol. 2008;22(1):45–63.PubMedCrossRef Spanier BW, Dijkgraaf MG, Bruno MJ. Epidemiology, aetiology and outcome of acute and chronic pancreatitis: an update. Best Pract Res Clin Gastroenterol. 2008;22(1):45–63.PubMedCrossRef
4.
go back to reference Lowenfels AB, Maisonneuve P, Cavallini G, et al. Pancreatitis and the risk of pancreatic cancer. International Pancreatitis Study Group. N Engl J Med. 1993;328(20):1433–7.PubMedCrossRef Lowenfels AB, Maisonneuve P, Cavallini G, et al. Pancreatitis and the risk of pancreatic cancer. International Pancreatitis Study Group. N Engl J Med. 1993;328(20):1433–7.PubMedCrossRef
5.
go back to reference Karlson BM, Ekbom A, Josefsson S, et al. The risk of pancreatic cancer following pancreatitis: an association due to confounding? Gastroenterology. 1997;113(2):587–92.PubMedCrossRef Karlson BM, Ekbom A, Josefsson S, et al. The risk of pancreatic cancer following pancreatitis: an association due to confounding? Gastroenterology. 1997;113(2):587–92.PubMedCrossRef
6.
go back to reference O’brien DP, Sandanayake NS, Jenkinson C, et al. Serum CA19-9 is significantly upregulated up to 2 years before diagnosis with pancreatic cancer: implications for early disease detection. Clin Cancer Res. 2015;21(3):622–31.PubMedCrossRef O’brien DP, Sandanayake NS, Jenkinson C, et al. Serum CA19-9 is significantly upregulated up to 2 years before diagnosis with pancreatic cancer: implications for early disease detection. Clin Cancer Res. 2015;21(3):622–31.PubMedCrossRef
7.
go back to reference Locker GY, Hamilton S, Harris J, et al. ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol. 2006;24(33):5313–27.PubMedCrossRef Locker GY, Hamilton S, Harris J, et al. ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol. 2006;24(33):5313–27.PubMedCrossRef
8.
go back to reference Deng T, Yuan Y, Zhang C, et al. Identification of circulating MiR-25 as a potential biomarker for pancreatic cancer diagnosis. Cell Physiol Biochem. 2016;39(5):1716–22.PubMedCrossRef Deng T, Yuan Y, Zhang C, et al. Identification of circulating MiR-25 as a potential biomarker for pancreatic cancer diagnosis. Cell Physiol Biochem. 2016;39(5):1716–22.PubMedCrossRef
9.
go back to reference Staal B, Liu Y, Barnett D, et al. The sTRA plasma biomarker: blinded validation of improved accuracy over CA19-9 in pancreatic cancer diagnosis. Clin Cancer Res. 2019;25(9):2745–54.PubMedPubMedCentralCrossRef Staal B, Liu Y, Barnett D, et al. The sTRA plasma biomarker: blinded validation of improved accuracy over CA19-9 in pancreatic cancer diagnosis. Clin Cancer Res. 2019;25(9):2745–54.PubMedPubMedCentralCrossRef
10.
go back to reference Zhang Y, Li X, Zhou D, et al. Inferences of individual drug responses across diverse cancer types using a novel competing endogenous RNA network. Mol Oncol. 2018;12(9):1429–46.PubMedPubMedCentralCrossRef Zhang Y, Li X, Zhou D, et al. Inferences of individual drug responses across diverse cancer types using a novel competing endogenous RNA network. Mol Oncol. 2018;12(9):1429–46.PubMedPubMedCentralCrossRef
11.
go back to reference Mcguire A, Brown JA, Kerin MJ. Metastatic breast cancer: the potential of miRNA for diagnosis and treatment monitoring. Cancer Metastasis Rev. 2015;34(1):145–55.PubMedPubMedCentralCrossRef Mcguire A, Brown JA, Kerin MJ. Metastatic breast cancer: the potential of miRNA for diagnosis and treatment monitoring. Cancer Metastasis Rev. 2015;34(1):145–55.PubMedPubMedCentralCrossRef
13.
go back to reference He B, Bai Y, Kang W, et al. LncRNA SNHG5 regulates imatinib resistance in chronic myeloid leukemia via acting as a CeRNA against MiR-205-5p. Am J Cancer Res. 2017;7(8):1704–13.PubMedPubMedCentral He B, Bai Y, Kang W, et al. LncRNA SNHG5 regulates imatinib resistance in chronic myeloid leukemia via acting as a CeRNA against MiR-205-5p. Am J Cancer Res. 2017;7(8):1704–13.PubMedPubMedCentral
14.
go back to reference Greco S, Gaetano C, Martelli F. Long noncoding competing endogenous RNA networks in age-associated cardiovascular diseases. Int J Mol Sci. 2019;20(12):3079.PubMedCentralCrossRef Greco S, Gaetano C, Martelli F. Long noncoding competing endogenous RNA networks in age-associated cardiovascular diseases. Int J Mol Sci. 2019;20(12):3079.PubMedCentralCrossRef
16.
go back to reference Zhang BF, Jiang H, Chen J, et al. LncRNA H19 ameliorates myocardial infarction-induced myocardial injury and maladaptive cardiac remodelling by regulating KDM3A. J Cell Mol Med. 2019;24(1):1099–1115.PubMedPubMedCentralCrossRef Zhang BF, Jiang H, Chen J, et al. LncRNA H19 ameliorates myocardial infarction-induced myocardial injury and maladaptive cardiac remodelling by regulating KDM3A. J Cell Mol Med. 2019;24(1):1099–1115.PubMedPubMedCentralCrossRef
17.
18.
go back to reference Kanehisa M, Goto S, Furumichi M, et al. KEGG for representation and analysis of molecular networks involving diseases and drugs. Nucleic Acids Res. 2010;38(Database issue):D355–60.PubMedCrossRef Kanehisa M, Goto S, Furumichi M, et al. KEGG for representation and analysis of molecular networks involving diseases and drugs. Nucleic Acids Res. 2010;38(Database issue):D355–60.PubMedCrossRef
19.
go back to reference Duan J, Soussen C, Brie D, et al. Generalized LASSO with under-determined regularization matrices. Signal Process. 2016;127:239–46.CrossRef Duan J, Soussen C, Brie D, et al. Generalized LASSO with under-determined regularization matrices. Signal Process. 2016;127:239–46.CrossRef
20.
go back to reference Taffel MT, Luk L, Ream JM, et al. Exploratory study of apparent diffusion coefficient histogram metrics in assessing pancreatic malignancy. Can Assoc Radiol J. 2019;70(4):416–23.PubMedCrossRef Taffel MT, Luk L, Ream JM, et al. Exploratory study of apparent diffusion coefficient histogram metrics in assessing pancreatic malignancy. Can Assoc Radiol J. 2019;70(4):416–23.PubMedCrossRef
21.
go back to reference Luo G, Zhang Y, Guo P, et al. Global patterns and trends in pancreatic cancer incidence: age, period, and birth cohort analysis. Pancreas. 2019;48(2):199–208.PubMedCrossRef Luo G, Zhang Y, Guo P, et al. Global patterns and trends in pancreatic cancer incidence: age, period, and birth cohort analysis. Pancreas. 2019;48(2):199–208.PubMedCrossRef
22.
go back to reference Tang J, Yu B, Li Y, et al. TGF-β-activated lncRNA LINC00115 is a critical regulator of glioma stem-like cell tumorigenicity. EMBO Rep. 2019;20(12):e48170.PubMedCrossRef Tang J, Yu B, Li Y, et al. TGF-β-activated lncRNA LINC00115 is a critical regulator of glioma stem-like cell tumorigenicity. EMBO Rep. 2019;20(12):e48170.PubMedCrossRef
24.
go back to reference Wang W, Lou W, Ding B, et al. A novel mRNA-miRNA-lncRNA competing endogenous RNA triple sub-network associated with prognosis of pancreatic cancer. Aging. 2019;11(9):2610–27.PubMedPubMedCentralCrossRef Wang W, Lou W, Ding B, et al. A novel mRNA-miRNA-lncRNA competing endogenous RNA triple sub-network associated with prognosis of pancreatic cancer. Aging. 2019;11(9):2610–27.PubMedPubMedCentralCrossRef
25.
go back to reference Bailey P, Chang DK, Nones K, et al. Genomic analyses identify molecular subtypes of pancreatic cancer. Nature. 2016;531(7592):47–52.PubMedCrossRef Bailey P, Chang DK, Nones K, et al. Genomic analyses identify molecular subtypes of pancreatic cancer. Nature. 2016;531(7592):47–52.PubMedCrossRef
26.
27.
go back to reference Zhu F, Dai SN, Xu DL, et al. EFNB2 facilitates cell proliferation, migration, and invasion in pancreatic ductal adenocarcinoma via the p53/p21 pathway and EMT. Biomed Pharmacother. 2020;125:109972.PubMedCrossRef Zhu F, Dai SN, Xu DL, et al. EFNB2 facilitates cell proliferation, migration, and invasion in pancreatic ductal adenocarcinoma via the p53/p21 pathway and EMT. Biomed Pharmacother. 2020;125:109972.PubMedCrossRef
28.
go back to reference Li C, Zhou D, Hong H, et al. TGFbeta1- miR-140-5p axis mediated up-regulation of Flap Endonuclease 1 promotes epithelial-mesenchymal transition in hepatocellular carcinoma. Aging. 2019;11(15):5593–612.PubMedPubMedCentral Li C, Zhou D, Hong H, et al. TGFbeta1- miR-140-5p axis mediated up-regulation of Flap Endonuclease 1 promotes epithelial-mesenchymal transition in hepatocellular carcinoma. Aging. 2019;11(15):5593–612.PubMedPubMedCentral
29.
go back to reference Wang LB, Feng L, He J, et al. MiR-125a-5p inhibits the proliferation and invasion of breast cancer cells and induces apoptosis by targeting GAB2. Math Biosci Eng. 2019;16(6):6923–33.PubMedCrossRef Wang LB, Feng L, He J, et al. MiR-125a-5p inhibits the proliferation and invasion of breast cancer cells and induces apoptosis by targeting GAB2. Math Biosci Eng. 2019;16(6):6923–33.PubMedCrossRef
30.
go back to reference Ding H, Luo Y, Hu K, et al. Linc00467 promotes lung adenocarcinoma proliferation via sponging miR-20b-5p to activate CCND1 expression. Onco Targets Ther. 2019;12:6733–43.PubMedPubMedCentralCrossRef Ding H, Luo Y, Hu K, et al. Linc00467 promotes lung adenocarcinoma proliferation via sponging miR-20b-5p to activate CCND1 expression. Onco Targets Ther. 2019;12:6733–43.PubMedPubMedCentralCrossRef
31.
go back to reference Tang D, Yang Z, Long F, et al. Long noncoding RNA MALAT1 mediates stem cell-like properties in human colorectal cancer cells by regulating miR-20b-5p/Oct4 axis. J Cell Physiol. 2019;234(11):20816–28.PubMedCrossRef Tang D, Yang Z, Long F, et al. Long noncoding RNA MALAT1 mediates stem cell-like properties in human colorectal cancer cells by regulating miR-20b-5p/Oct4 axis. J Cell Physiol. 2019;234(11):20816–28.PubMedCrossRef
32.
go back to reference Moore PC, Qi JY, Thamsen M, et al. Parallel signaling through IRE1alpha and PERK regulates pancreatic neuroendocrine tumor growth and survival. Cancer Res. 2019;79(24):6190–203.PubMedPubMedCentralCrossRef Moore PC, Qi JY, Thamsen M, et al. Parallel signaling through IRE1alpha and PERK regulates pancreatic neuroendocrine tumor growth and survival. Cancer Res. 2019;79(24):6190–203.PubMedPubMedCentralCrossRef
33.
34.
go back to reference Abdel-Wahab AF, Mahmoud W, Al-Harizy RM. Targeting glucose metabolism to suppress cancer progression: prospective of anti-glycolytic cancer therapy. Pharmacol Res. 2019;150:104511.CrossRefPubMed Abdel-Wahab AF, Mahmoud W, Al-Harizy RM. Targeting glucose metabolism to suppress cancer progression: prospective of anti-glycolytic cancer therapy. Pharmacol Res. 2019;150:104511.CrossRefPubMed
Metadata
Title
Identification of a competing endogenous RNA network associated with prognosis of pancreatic adenocarcinoma
Authors
Wanqing Weng
Zhongjing Zhang
Weiguo Huang
Xiangxiang Xu
Boda Wu
Tingbo Ye
Yunfeng Shan
Keqing Shi
Zhuo Lin
Publication date
01-12-2020
Publisher
BioMed Central
Published in
Cancer Cell International / Issue 1/2020
Electronic ISSN: 1475-2867
DOI
https://doi.org/10.1186/s12935-020-01243-6

Other articles of this Issue 1/2020

Cancer Cell International 1/2020 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine